Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
) has been revised to $84.57 / share. This is an increase of 18.76% from the prior estimate of $71.21 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
TD Cowen analyst Dan Brennan lowered the firm’s price target on Exact Sciences (EXAS) to $82 from $90 and keeps a Buy rating on the shares. The firm said they reporrted a modest 3Q miss and a material ...
BofA lowered the firm’s price target on Exact Sciences (EXAS) to $72 from $75 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech ...
Craig-Hallum raised the firm’s price target on Exact Sciences (EXAS) to $85 from $65 and keeps a Buy rating on the shares. The firm would be a buyer of Exact Sciences. With the Freenome deal in place ...
View Caris Life Sciences, Inc. CAI stock quote prices, financial information, real-time forecasts, and company news from CNN.
The average one-year price target for Exact Sciences (NasdaqCM:EXAS) has been revised to $84.57 / share. This is an increase of 18.76% from the prior estimate of $71.21 dated November 7, 2025. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results